N. Manojlovic

发表

Efficacy and safety of bevacizumab in combination with oxaliplatin, irinotecan and fluoropyrimidine-based therapy in advanced colorectal cancer

A. Dagović, S. Jezdic, B. Kukic, 2007 .

Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx®): a placebo-controlled randomised phase II study (PLIANT)

D. Mahalingam, B. Glimelius, P. Pfeiffer, 2017, Acta oncologica.

Perioperative bevacizumab treatment of colorectal cancer patients with liver metastases: results of RELEVANT observational trial

I. Nikolić, V. Kovčin, Z. Radosavljevic, 2019 .

A controversial issue: could a watch‐and‐wait policy for patients with non‐Hodgkin's lymphoma clinical stage I or IE with no lymphoma left following diagnostic surgery be justified? Results of a single centre study

S. Jelić, D. Gavrilovic, N. Manojlovic, 1997 .

Perioperative bevacizumab in the treatment of colorectal cancer in patients with liver metastases

D. Radosavljevic, I. Nikolic, Z. Andrić, 2022, Medical review.

The Usefulness of Prognostic Nutritional Index in Predicting Infection in Patients with Newly Diagnosed Pancreatic Cancer

N. Manojlovic, Saša Perić, B. Roganović, 2021, Biomedical Journal of Scientific & Technical Research.

SEROREACTIVITY AGAINST HELICOBACTER PYLORI ANTIGENS VACA,30 KDA AND 50 KDA IS A BETTER BIOMARKER APPROACH FOR THE OUTCOME OF INFECTION THAN VACA AND 50 KDA ALONE ISTOVREMENA I ALTERNATIVNA IGG SEROREAKTIVNOST PROTIV HELICOBACTER PYLORI ANTIGENA

E. Ristanovic, I. Tufegdžić, N. Manojlovic, 2020 .

Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer

M. Hidalgo, E. Van Cutsem, E. Raymond, 2018, International journal of cancer.

A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer

Joon-Oh Park, Tae Won Kim, C. Lofton-Day, 2016, British Journal of Cancer.

Dynamic monitoring of carcinoembryonic antigen, CA19-9 and inflammation-based indices in patients with advanced colorectal cancer undergoing chemotherapy

N. Rančić, B. Nikolić, N. Manojlovic, 2022, World journal of clinical cases.

Namodenoson in Advanced Hepatocellular Carcinoma and Child–Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial

P. Fishman, T. Ciuleanu, A. Croitoru, 2021, Cancers.

Anti Helicobacter pylori IgG and IgA response in patients with gastric cancer and chronic gastritis.

N. Manojlovic, D. Babić, Ivana Filipovic-Ljeshovic, 2008, Hepato-gastroenterology.

Antiplatelet agents'-ticagrelol and eptifibatide-safety in experimental colitis in mice.

N. Rančić, S. Obradovic, R. Doder, 2020, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer.

W. Guo, M. Hidalgo, J. Canon, 2015 .

Seroreactivity against Helicobacter pylori VacA,50kDa and 30kDa along with alarm features may improve the diagnostic approach to uninvestigated dyspepsia: A pilot study

E. Ristanovic, D. Bokonjić, I. Tufegdžić, 2022, Vojnosanitetski pregled.

Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer

Joon-Oh Park, Tae Won Kim, C. Lofton-Day, 2018, Clinical colorectal cancer.

Efficacy and safety of bevacizumab in combination with oxaliplatin, irinotecan and fluoropyrimidine-based therapy in advanced colorectal cancer

A. Dagović, S. Jezdic, B. Kukic, 2007 .

Capecitabine cardiotoxicity--case reports and literature review.

I. Filipović, N. Manojlovic, D. Babić, 2008, Hepato-gastroenterology.